Armata Pharmaceuticals Inc ARMP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
Trading Information
- Previous Close Price
- $2.98
- Day Range
- $2.89–3.19
- 52-Week Range
- $2.40–14.98
- Bid/Ask
- $2.98 / $3.28
- Shares Outstanding
- 37.19M
- Market Cap
- $112.69M
- Volume/Avg
- 85,853 / 182,170
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 61
- Website
- https://www.armatapharma.com
Valuation
Metric | ARMP |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ARMP |
|---|---|
Quick Ratio | 0.12 |
Current Ratio | 0.12 |
Interest Coverage | −3.52 |
Quick Ratio
ARMP
Profitability
Metric | ARMP |
|---|---|
Return on Assets (Normalized) | −119.23% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −98.70% |
Return on Assets
ARMP
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<^l%&>% | LOCK|>>bM | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#!#XY> | LOCK|>fv@ | $95B | |||
| Moderna Inc MRNA | LOCK|%k&Kc? | LOCK|cTd | $79B | |||
| argenx SE ADR ARGX | LOCK|jdb!qCq | LOCK|Hh | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|THt<vXv | LOCK|Hrm | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|D^t%Rv> | LOCK|tJNN! | $30B | |||
| Incyte Corp INCY | LOCK|j$&GbC | LOCK|rL | $23B | |||
| BioNTech SE ADR BNTX | LOCK|jMj&b< | LOCK|X% | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>#h#@# | LOCK|PlSd | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|%!Ckb?$ | LOCK|&V | $15B |